Olema Pharmaceuticals, Inc. (OLMA) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 8 Buy.
The consensus price target is $42.50 (low: $38.00, high: $48.00), representing an upside of 160.7% from the current price $16.30.
Analysts estimate Earnings Per Share (EPS) of $-2.30 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.20 vs est $-2.30 (beat +4.4%). 2025: actual $-1.87 vs est $-1.89 (beat +1.1%). Analyst accuracy: 97%.
OLMA Stock — 12-Month Price Forecast
$42.50
▲ +160.74% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Olema Pharmaceuticals, Inc., the average price target is $42.50, with a high forecast of $48.00, and a low forecast of $38.00.
The average price target represents a +160.74% change from the last price of $16.30.
Highest Price Target
$48.00
Average Price Target
$42.50
Lowest Price Target
$38.00
OLMA Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Olema Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — OLMA
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.20
vs Est –$2.30
▲ 4.6% off
2025
Actual –$1.87
vs Est –$1.89
▲ 1.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — OLMA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
